

WE CLAIM:

1. A method of treating non-small cell lung cancer in a patient, comprising administering to a non-small cell lung cancer patient in need of such treatment an effective amount of a compound of the formula:



or a pharmaceutically acceptable salt thereof, in combination with an effective amount of an antibody comprising a light chain variable region (LCVR) whose amino acid sequence is that given in SEQ ID NO: 2, and a heavy chain variable region (HCVR) whose amino acid sequence is that given in SEQ ID NO: 4, wherein that the antibody binds to VEGFR2.

2. The method of claim 1, wherein the compound is



.

3. The method of claim 2 wherein the antibody comprises a light chain whose amino acid sequence is that given in SEQ ID NO: 6, and a heavy chain whose amino acid sequence is that given in SEQ ID NO: 8 and the antibody binds to VEGFR2


4. The method of claim 3, wherein the antibody is ramucirumab.

~~5. The method of claim 4 wherein the compound or salt thereof is administered at a dose of between about 100 mg/day to about 400 mg/day and ramucirumab is administered once every three weeks at a dose of between about 6 mg/kg to about 10 mg/kg.~~

~~6. The method of claim 5 wherein the compound or salt thereof is administered orally and ramucirumab is administered intravenously.~~

WE CLAIM:

~~7.~~1. A kit comprising a compound of the formula:




or a pharmaceutically acceptable salt thereof, and an antibody comprising a light chain variable region (LCVR) whose amino acid sequence is that given in SEQ ID NO: 2, and a heavy chain variable region (HCVR) whose amino acid sequence is that given in SEQ ID NO: 4, wherein that the antibody binds to VEGFR2.


~~8.~~2. The kit of claim ~~7~~ 1 wherein the antibody comprises a light chain whose amino acid sequence is that given in SEQ ID NO: 6, and a heavy chain whose amino acid sequence is that given in SEQ ID NO: 8 and the antibody binds to VEGFR2.

~~9.~~3. The kit of claim ~~8~~ 2 wherein the antibody is ramucirumab.

~~10.~~4. The kit of claim ~~9~~ 3 wherein the compound is



~~11.~~5. A kit, comprising a pharmaceutical composition, comprising a compound of the formula:




or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers, diluents, or excipients, and a pharmaceutical composition, comprising ramucirumab, with one or more pharmaceutically acceptable carriers, diluents, or excipients.

~~12.~~6. A combination comprising [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine or a pharmaceutically acceptable salt thereof and an anti-VEGFR2 Ab for simultaneous, separate or sequential use in the treatment of NSCLC.


~~13.~~7. The combination of claim ~~12~~ 6 wherein the anti-VEGFR2 Ab is ramucirumab.

~~14~~8. A compound of the formula:



or a pharmaceutically acceptable salt thereof, in combination with ramucirumab.

159. A compound of the formula:



or a pharmaceutically acceptable salt thereof, in combination with ramucirumab for use in the treatment of non-small cell lung cancer.